Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 42 Records) |
| Query Trace: Colorectal Neoplasms and MUT[original query] |
|---|
| The association between MTHFR 677C>T genotype and folate status and genomic and gene-specific DNA methylation in the colon of individuals without colorectal neoplasia. The American journal of clinical nutrition 2013 Dec 98 (6): 1564-74. Hanks Joanna, Ayed Iyeman, Kukreja Neil, Rogers Chris, Harris Jessica, Gheorghiu Alina, Liu Chee Ling, Emery Peter, Pufulete Mar |
| The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta oncologica (Stockholm, Sweden) 2014 Jul 53 (7): 877-84. Sommeijer Dirkje W, Karapetis Christos S, Zalcberg John R, Tu Dongsheng, Jonker Derek J, Simes John, Tebbutt Niall, Yip Desmond, Price Timothy J, O'Callaghan Chris |
| Somatic mutations of amino acid metabolism-related genes in gastric and colorectal cancers and their regional heterogeneity--a short report. Cellular oncology (Dordrecht) 2014 Dec 37 (6): 455-61. Oh Hye Rim, An Chang Hyeok, Yoo Nam Jin, Lee Sug Hyu |
| Genetic modifiers of folate, vitamin B-12, and homocysteine status in a cross-sectional study of the Canadian population. The American journal of clinical nutrition 2015 Jun 101 (6): 1295-304. Zinck John Wr, de Groh Margaret, MacFarlane Amanda |
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. European journal of cancer (Oxford, England : 1990) 2015 Mar 51 (5): 587-94. Pietrantonio Filippo, Petrelli Fausto, Coinu Andrea, Di Bartolomeo Maria, Borgonovo Karen, Maggi Claudia, Cabiddu Mary, Iacovelli Roberto, Bossi Ilaria, Lonati Veronica, Ghilardi Mara, de Braud Filippo, Barni Sand |
| A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 Oct . Hagman H, Frödin J-E, Berglund Å, Sundberg J, Weber Vestermark L, Albertsson M, Fernebro E, Johnsson |
| Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdominal radiology (New York) 2016 Sep . Magnetta Michael J, Ghodadra Anish, Lahti Steven J, Xing Minzhi, Zhang Di, Kim Hyun |
| Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers. Journal of the National Cancer Institute 2016 12 108 (12): . Wang Zhenghe, Li Li, Guda Kishore, Chen Zhengyi, Barnholtz-Sloan Jill, Park Young Soo, Markowitz Sanford D, Willis Jose |
| From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. Surgical oncology 2016 Sep 25 (3): 332-8. Andreatos Nikolaos, Ronnekleiv-Kelly Sean, Margonis Georgios A, Sasaki Kazunari, Gani Faiz, Amini Neda, Wilson Ana, Pawlik Timothy |
| CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. Oncoimmunology 2016 5 (12): e1254313. D'Alterio Crescenzo, Nasti Guglielmo, Polimeno Marianeve, Ottaiano Alessandro, Conson Manuel, Circelli Luisa, Botti Giovanni, Scognamiglio Giosuè, Santagata Sara, De Divitiis Chiara, Nappi Anna, Napolitano Maria, Tatangelo Fabiana, Pacelli Roberto, Izzo Francesco, Vuttariello Emilia, Botti Gerardo, Scala Stefan |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of gastrointestinal oncology 2018 Aug 9 (4): 610-617. Fabrizio David A, George Thomas J, Dunne Richard F, Frampton Garrett, Sun James, Gowen Kyle, Kennedy Mark, Greenbowe Joel, Schrock Alexa B, Hezel Aram F, Ross Jeffrey S, Stephens Phillip J, Ali Siraj M, Miller Vincent A, Fakih Marwan, Klempner Samuel |
| Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA surgery 2018 May e180996. Margonis Georgios Antonios, Buettner Stefan, Andreatos Nikolaos, Kim Yuhree, Wagner Doris, Sasaki Kazunari, Beer Andrea, Schwarz Christoph, Løes Inger Marie, Smolle Maria, Kamphues Carsten, He Jin, Pawlik Timothy M, Kaczirek Klaus, Poultsides George, Lønning Per Eystein, Cameron John L, Burkhart Richard A, Gerger Armin, Aucejo Federico N, Kreis Martin E, Wolfgang Christopher L, Weiss Matthew |
| Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. Oncotarget 2018 5 9 (29): 20539-20554. Correale Pierpaolo, Botta Cirino, Staropoli Nicoletta, Nardone Valerio, Pastina Pierpaolo, Ulivieri Cristina, Gandolfo Claudia, Baldari Tatiana Cosima, Lazzi Stefano, Ciliberto Domenico, Giannicola Rocco, Fioravanti Antonella, Giordano Antonio, Zappavigna Silvia, Caraglia Michele, Tassone Pierfrancesco, Pirtoli Luigi, Cusi Maria Grazia, Tagliaferri Pierosand |
| Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Scientific reports 2019 Jun 9 (1): 8976. Vivancos Ana, Aranda Enrique, Benavides Manuel, Élez Elena, Gómez-España Maria Auxiliadora, Toledano Marta, Alvarez Martina, Parrado Maria Rosario Chica, García-Barberán Vanesa, Diaz-Rubio Eduar |
| Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. The oncologist 2019 5 24 (10): 1340-1347. Parikh Aparna R, He Yuting, Hong Ted S, Corcoran Ryan B, Clark Jeff W, Ryan David P, Zou Lee, Ting David T, Catenacci Daniel V, Chao Joseph, Fakih Marwan, Klempner Samuel J, Ross Jeffrey S, Frampton Garrett M, Miller Vincent A, Ali Siraj M, Schrock Alexa |
| Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients. Annals of surgery 2020 Aug 272 (2): 352-356. Gholami Sepideh, Kemeny Nancy E, Boucher Taryn M, Gönen Mithat, Cercek Andrea, Kingham T Peter, Balachandran Vinod, Allen Peter, DeMatteo Ronald, Drebin Jeffrey, Jarnagin William, D'Angelica Micha |
| WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers 2020 5 12 (5): . Zimmer Kai, Puccini Alberto, Xiu Joanne, Baca Yasmine, Spizzo Gilbert, Lenz Heinz-Josef, Battaglin Francesca, Goldberg Richard M, Grothey Axel, Shields Anthony F, Salem Mohamed E, Marshall John L, Korn W Michael, Wolf Dominik, Kocher Florian, Seeber Andre |
| Smoking, alcohol consumption and colorectal cancer risk by molecular pathological subtypes and pathways. British journal of cancer 2020 Mar . Amitay Efrat L, Carr Prudence R, Jansen Lina, Roth Wilfried, Alwers Elizabeth, Herpel Esther, Kloor Matthias, Bläker Hendrik, Chang-Claude Jenny, Brenner Hermann, Hoffmeister Micha |
| Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. Clinical chemistry 2020 Nov . Lueong Smiths S, Herbst Andreas, Liffers Sven-Thorsten, Bielefeld Nicola, Horn Peter A, Tannapfel Andrea, Reinacher-Schick Anke, Hinke Axel, Hegewisch-Becker Susanna, Kolligs Frank T, Siveke Jens |
| Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns. Cancer medicine 2020 10 10 (1): 135-142. Hu Hanguang, Cai Wen, Wu Dehao, Hu Wangxiong, Dong Wang Li, Mao Jianshan, Zheng Shu, Ge Weiti |
| Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. European journal of cancer (Oxford, England : 1990) 2021 Aug 155 73-84. Antoniotti Carlotta, Korn W Michael, Marmorino Federica, Rossini Daniele, Lonardi Sara, Masi Gianluca, Randon Giovanni, Conca Veronica, Boccaccino Alessandra, Tomasello Gianluca, Passardi Alessandro, Swensen Jeff, Ugolini Clara, Oberley Matthew, Tamburini Emiliano, Casagrande Mariaelena, Domenyuk Valeriy, Fontanini Gabriella, Giordano Mirella, Abraham Jim, Spetzler David, Falcone Alfredo, Lenz Heinz-Josef, Cremolini Chia |
| Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO open 2021 Mar 6 (2): 100093. Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara |
| Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer. Human vaccines & immunotherapeutics 2021 Mar 1-11. Yu Yaojun, Zhang Jing, Ni Leyi, Zhu Yuesheng, Yu Hejie, Teng Yangyang, Lin Limiao, Xue Zhanxiong, Xue Xiangyang, Shen Xian, Song Haiping, Su Xiaoping, Sun Weihong, Cai Zhenzh |
| Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
| NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer medicine 2022 5 11 (13): 2541-2549. Wang Hui, Li Zhi-Wei, Ou Qiuxiang, Wu Xue, Nagasaka Misako, Shao Yang, Ou Sai-Hong Ignatius, Yang |
| Morbidity and long-term results in patients with wild and mutant type Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations undergoing colorectal cancer surgery. Annali italiani di chirurgia 2022 3 92 65-77. Aziret Mehmet, Subasi Ozkan, Bilir Cemil, Tozlu Mukaddes, Alt?ntoprak Fatih, Karaman Kerem, Ercan Metin, Celebi Feh |
| Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. Journal for immunotherapy of cancer 2022 2 10 (1): . Zheng Mi |
| Using genotype to assist clinical surveillance: a retrospective study of Chinese familial adenomatous polyposis patients. American journal of cancer research 2022 10 12 (9): 4254-4266. Ge Sai, Cheng Duo, Zhang Xuhui, Xu Ting, Wang Zhenghang, Dong Fengxiao, Su Lan, Song Jinlei, Wang Jia, Li Jian, Shen Lin, Wang Xiche |
| Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. European journal of cancer (Oxford, England : 1990) 2023 4 187 15-24. Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola, Chiara Boccaccio, Gianmarco Ricagno, Filippo Ghelardi, Giovanni Randon, Giuseppe Leoncini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietranton |
| Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023 2 36 (2): 100012. Berrino Enrico, Aquilano Maria Costanza, Valtorta Emanuele, Amodio Vito, Germano Giovanni, Gusmini Marco, Gizzi Katiuscia, Fenocchio Elisabetta, Sapino Anna, Marsoni Silvia, Sartore-Bianchi Andrea, Bardelli Alberto, Siena Salvatore, Bonoldi Emanuela, Marchiò Cateri |
- Page last reviewed:Feb 1, 2023
- Page last updated:May 22, 2023
- Content source: